Relmada Therapeutics has reported promising 12-month data from its Phase II study of NDV01, a sustained-release formulation targeting high-risk non-muscle invasive bladder cancer (NMIBC). The treatment achieved a complete response rate of 76% overall, with an impressive 80% in the BCG-unresponsive subgroup. Importantly, the safety profile showed no progression to muscle-invasive disease or severe treatment-related adverse events, bolstering its potential as a leading therapy in this challenging market.
The upcoming Phase III RESCUE program, set to begin mid-year, will explore two registrational pathways: one for adjuvant therapy in intermediate-risk bladder cancer and another for second-line treatment in BCG-unresponsive patients. This dual approach not only aligns with FDA requirements but also positions NDV01 favorably against existing therapies, which could significantly impact market dynamics as it addresses unmet medical needs in these patient populations.
For investors, Relmada’s robust financing—$160 million from private placements and an additional $94 million from a stock offering—extends its operational runway through 2029, ensuring that the NDV01 program can reach critical milestones. This financial stability, combined with strong clinical data, makes Relmada a company to watch as it advances its promising bladder cancer treatment.
Source: fool.com